Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

For low- and middle-income countries – so-called developing economies – growth is expected to come in at 4.1% this year and slow slightly to 4% in 2026. The World Bank says that plodding pace of ...

Deep-pocketed investors have adopted a bearish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and endoscopic response rates in patients with Crohn disease. The FDA has ...

Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn's disease, an inflammatory bowel disease that causes chronic abdominal pain.

Eli Lilly (LLY) announced that the FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for two types of ...

Government policies and regulations are uncontrollable and the good news is that for a business such as Eli Lilly, which is developing potentially life-changing treatments for patients ...

Eli Lilly announced preliminary fourth-quarter ... such as portfolio management or data aggregation. Develop and improve features of our offerings. Gear advertisements and other marketing efforts ...

It’s about going home. Former New York Giants quarterback Eli Manning is heading back to the Big Easy for Super Bowl LIX at the Caesars Superdome (happening February 9, 2025) and his return comes with ...

Eli Lilly is developing an obesity pill that would be more convenient for patients and easier to manufacture, and Ricks expects it to be approved as soon as early next year. "While the U.S ...